Focused On-demand Library for Doublecortin domain-containing protein 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9UHG0

UPID:
DCDC2_HUMAN

ALTERNATIVE NAMES:
Protein RU2S

ALTERNATIVE UPACC:
Q9UHG0; Q5VTR8; Q5VTR9; Q86W35; Q9UFD1; Q9UHG1; Q9ULR6

BACKGROUND:
The Doublecortin domain-containing protein 2, or Protein RU2S, is integral to the inhibition of the Wnt signaling pathway, which influences various developmental processes. Its involvement in neuronal migration and ciliogenesis underscores its importance in brain development and cellular function regulation.

THERAPEUTIC SIGNIFICANCE:
Linked to diseases such as Dyslexia 2, Nephronophthisis 19, autosomal recessive Deafness 66, and neonatal Sclerosing cholangitis, Protein RU2S's role in these conditions suggests its utility in developing treatments for a range of genetic disorders. The exploration of Protein RU2S's functions offers promising avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 176 of 8789